Table 1 Baseline characteristics of women who initiated bisphosphonate treatment
From: Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
Characteristics | All Women (N = 87,820) |
|---|---|
Cohort entry year before 2008 | 47,771 (54.4%) |
Age, mean ± SD | 68.6 ± 9.1 |
Race/Ethnicity | |
 White | 57,680 (65.7%) |
 African-American/Black | 3321 (3.8%) |
 Hispanic/Latina | 9177 (10.4%) |
 Asian/Pacific-Islander | 15,761 (17.9%) |
 Other/Mixed/Unknown | 1881 (2.1%) |
Index Body Mass Index Category (kg/m2) | |
 Normal/Underweight (BMI < 25) | 46,399 (52.8%) |
 Overweight (BMI 25 to < 30) | 28,354 (32.3%) |
 Obese (BMI ≥30) | 13,067 (14.9%) |
Current Smoking | 12,729 (14.5%) |
Estimated low educational attainment based on US Census block | 11,313 (12.9%) |
Estimated low household income based on US Census block | 5013 (5.7%) |
Charlson Comorbidity Index (Deyo modification) | |
 0 | 50,993 (58.1%) |
 1–2 | 27,285 (31.1%) |
 ≥ 3 | 9542 (10.9%) |
History of medical conditions | |
 Diabetes | 6544 (7.5%) |
 Rheumatoid arthritis | 3000 (3.4%) |
 Grade 3 chronic kidney disease (eGFR 59–30 mL/min/1.7m2) | 15,350 (17.5%) |
 Vitamin D deficiency (25OHD < 20 ng/mL) | 14,459 (16.5%) |
Relevant medication exposures | |
 Estrogen | 5355 (6.1%) |
 Raloxifene | 355 (0.4%) |
 Aromatase inhibitors | 1792 (2.0%) |
 Proton pump inhibitors | 10,070 (11.5%) |
 Glucocorticoids (prednisone equivalent 1825 mg/year) | 3401 (3.9%) |
Fracture history in the five years prior to bisphosphonate initiation | |
 Major osteoporotic fracture a | 12,575 (14.3%) |
 Any clinical fracture | 23,391 (26.6%) |
Bone mineral density | 63,595 (72.4%) |
 T-Score, median (IQR) | −2.6 (−3.0, − 2.0) |
 Osteoporosis b | 37,420 (58.8%) |
 Osteopenia b | 23,549 (37.0%) |